Sponsor:
Limacorporate S.p.a
Code:
NCT03048201
Conditions
Osteoarthritis, Knee
Traumatic Arthritis
Avascular Necrosis
Degenerative Joint Disease of Knee
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 22+
Healthy Volunteers: Not accepted
Interventions
Physica Kinematic Retaining Knee System
Physica Cruciate Retaining Knee System
Physica Posterior Stabilized Knee System
Physica Cruciate Retaining Knee System with LMC Liner
Brief summary:
Conditions
Osteoarthritis, Knee
Traumatic Arthritis
Avascular Necrosis
Degenerative Joint Disease of Knee
Rheumatoid Arthritis
Study ID
NCT03048201
Start date
Mar 24, 2017
Status verified date
Mar, 2023
Completion date
Mar, 2030
Anticipated
Primary completion date
Mar, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 22+
Healthy Volunteers: Not accepted
Enrollment
800 participants
Anticipated
Allocation
Non randomized
Intervention Model
Single group
Primary purpose
Treatment
Arms
other: Physica KR
other: Physica CR
other: Physica PS
other: Physica CR with LMC Liner
Interventions
Physica Kinematic Retaining Knee System
Physica Cruciate Retaining Knee System
Physica Posterior Stabilized Knee System
Physica Cruciate Retaining Knee System with LMC Liner
Primary outcome measure
Central contacts
Federica Azzimonti
federica.azzimonti@limacorporate.comLocations
Eisenhower Desert Orthopedics Center - Harry and Diane Rinker Bldg
Recruiting
Rancho Mirage, California, United States, 92270
Contacts
Principal Investigator:
Erik Schnaser, MD
The Orthopedics Clinic
Recruiting
Daytona Beach, Florida, United States, 32117
Contacts
Mark Gillespy, MD
386-255-4596Sherri Zicker
+1-386-255-4596Principal Investigator:
Mark Gillespy, MD
Rush Castle Orthopaedics
Recruiting
Aurora, Illinois, United States, 60504
Contacts
Mark Schinsky, MD
630-978-3800Renee Bergstrom
+1-630-978-3800Principal Investigator:
Mark Schinsky, MD
Sponsor
Limacorporate S.p.a
Last update posted
Mar 21, 2023
Last verified
Mar, 2023
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Limacorporate S.p.a on 2023-03-21.